FDA Expands Approval for RSV Vaccine, Now Available for Adults Over 50
Credit: Getty Images
The Food and Drug Administration (FDA) has recently approved an expansion of a respiratory syncytial virus (RSV) vaccine for use in at-risk adults over the age of 50.
Manufactured by British multinational pharmaceutical and biotechnology company GSK, this vaccine is the first to be approved for adults aged 50–59, targeting a virus known for causing severe respiratory issues, particularly in older adults and those with pre-existing health conditions.
RSV is a common respiratory virus that primarily infects the lungs, nose, throat, and breathing passages. It typically causes mild cold-like symptoms such as a runny nose, fever, cough, and wheezing.
“Today’s approval reflects the importance of broadening the benefits of RSV immunization to adults aged 50-59 who are at increased risk,” said Tony Wood,
